Business Context and Reporting Period
This Form 8-K was filed by Sunshine Heart, Inc. on March 6, 2015. The registrant is a Delaware corporation headquartered in Eden Prairie, Minnesota. The filing serves as a Regulation FD disclosure regarding an update on the COUNTER HF study, a pivotal clinical trial for the company's C-Pulse heart assist system.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on clinical study updates and does not contain financial statements.
Material Changes
The material event reported is the issuance of a press release updating the status of the COUNTER HF study. This study is a prospective, randomized, multi-center, controlled trial evaluating the safety and efficacy of the C-Pulse system for treating NYHA Class III and ambulatory Class IV heart failure. The study specifically assesses the system's balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations.
Guidance, Outlook, and Risks
Management commentary is limited to the description of the COUNTER HF study objectives. The filing explicitly states that the information, including the attached press release (Exhibit 99.1), is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the information is not subject to the liabilities of that section and will not be deemed an admission as to the materiality of any information required solely by Regulation FD. No specific financial guidance or risk factors are detailed within the text of this 8-K.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for specific study results or timelines not summarized in the 8-K.
- Confirm the current status of the C-Pulse system regulatory approval process.
- Review the company's most recent 10-K or 10-Q filings for financial metrics, as this 8-K contains no financial data.
- Monitor for future filings regarding the completion or outcomes of the COUNTER HF study.